By carefully calibrating N/OFQ administration, balanced coactivation of OPRL1 and mu opioid receptors is a strategy that warrants further exploration and refinement to manage cancer pain, thereby limiting opioid-associated side effects. This evidence concerns the gene OPRL1 and cancer.